Healthcare Payors Model Risk Vendor Selection | Moring
Vendor selection is a model risk decision for healthcare payors because most models arrive embedded in purchased products. Selection should assess the vendor's governance program, data handling and training use, model documentation and change notification, security testing, and sub-processor exposure, and then convert those findings into contract terms that produce dated, verifiable evidence rather than assurances.
Short answer
Vendor selection is a model risk decision for healthcare payors because most models arrive embedded in purchased products. Selection should assess the vendor's governance program, data handling and training use, model documentation and change notification, security testing, and sub-processor exposure, and then convert those findings into contract terms that produce dated, verifiable evidence rather than assurances.
How it works
Payors increasingly do not build their models; they buy them inside utilization management, prior authorization, payment integrity, and member engagement products. That makes vendor selection the moment where model risk is either controlled or inherited, because the buyer acquires the vendor's control boundaries along with the capability. Analysis of AI vendor risk management makes the point plainly: a weak provider control becomes the customer's operational problem, especially when the AI service is embedded in business workflows, handles sensitive inputs, or acts with broad permissions.
The scale of third-party exposure in healthcare is measurable and large. In 2024, 663 large healthcare breaches were reported, affecting 243 million individuals, and while business associates accounted for only about 16 percent of those incidents, they were tied to roughly 85 percent of the affected people. Whatever the exact distribution in a given year, the direction is consistent: the most damaging exposures often sit with vendors rather than inside the plan, which is precisely why model risk management has to reach into procurement rather than starting after signature.
Assessment should cover a defined set of domains rather than a questionnaire of impressions. The material questions are whether the vendor maintains a real AI governance program with named accountability, how the payor's data is handled and whether it trains the vendor's models, how transparent the model and its documentation are, what security testing the vendor runs against AI-specific attacks, which sub-processors and fourth-party model dependencies sit underneath, and what commitments exist for notifying the payor of model changes. Equally important is mapping which deployment-side controls remain the payor's own, because a vendor certificate covers the vendor, not how the plan configures, integrates, and monitors the tool.
Contract terms convert assessment into enforceable obligations. Practical guidance for healthcare AI vendors and their customers converges on a short list: a dated, independently verifiable governance record delivered at signing and quarterly, with the monitoring burden placed on the vendor; explicit model change notice periods; incident notification obligations; audit rights; and exit provisions that address model and data portability. A committee charter is not evidence, and the contracting moment is the last point at which a payor can require the vendor to produce the record rather than describe it.
Industry developments reinforce the direction of travel. Recent guidance from healthcare quality and safety bodies emphasizes AI governance, safety event reporting, and vendor management as the mechanisms for responsible use, and startup and health system executives alike report that resource and infrastructure constraints make scalable, standardized monitoring systems necessary, which favors vendors who can produce evidence over vendors who can only produce demonstrations. A selection process that scores evidence production capability, not just model performance, aligns with where the market is being pushed.
Selection decisions should also anticipate the EU AI Act, because obligations can flow through the chain to the deployer. A payor deploying an in-scope vendor system retains responsibilities for documentation, human oversight, and logging that the vendor cannot absorb by contract alone, so the selection file should record which obligations each party holds and how evidence will flow. Payors that treat vendor selection as a model risk control, with the same rigor applied to a claims-edit model as to a network vendor, enter deployment with the evidence trail already started.
Scoring discipline keeps vendor selection honest, because model demonstrations are engineered to impress and questionnaires are engineered to pass. The selection scorecard should weight evidence production, the vendor's ability to deliver the dated governance record, model change notices, and monitoring data in a form the payor can ingest, at least as heavily as headline model performance, and it should include a reference check that asks existing healthcare customers what evidence they actually receive rather than what was promised. Payors should also score exit readiness: how cleanly the plan could replace the vendor's model, what data portability exists, and how long the fallback process would carry the workload. Selection files should record the reasoning, not just the scores, since a decision reviewed two years later needs the context of what alternatives were considered and what tradeoffs were accepted. Treating the selection file as the first entry in the model's lifecycle evidence, rather than procurement paperwork, aligns the commercial process with the governance one.
Frequently asked questions
What should a healthcare payor assess when selecting an AI model vendor?
Assess the vendor's governance program and named accountability, how the plan's data is handled and whether it trains the vendor's models, the transparency of model documentation, security testing against AI-specific attacks, sub-processor and fourth-party dependencies, and model change notification commitments. Equally important is mapping which controls remain on the payor's side, because a vendor attestation covers the vendor, not how the plan configures, integrates, and monitors the deployed system.
Which contract terms matter most for payor AI model vendors?
The terms that produce evidence: a dated, independently verifiable governance record at signing and quarterly, monitoring obligations placed on the vendor, model change notice periods, incident notification, audit rights, and exit provisions covering data and model portability. These convert due diligence from a point-in-time questionnaire into a continuous obligation. Without them, a payor's post-deployment oversight depends on vendor goodwill rather than contract.
Why is vendor risk elevated in healthcare payor AI deployments?
Because the data is sensitive, the workflows are consequential, and the exposure is demonstrably concentrated outside the plan: 2024 healthcare breach data showed business associates tied to roughly 85 percent of affected individuals despite representing a minority of incidents. Vendors embedded in utilization management, prior authorization, and payment integrity workflows inherit broad permissions and sensitive inputs, so a weak vendor control becomes the payor's operational and regulatory problem.
How does the EU AI Act affect vendor selection for payors?
Deployers of in-scope systems retain obligations for documentation, human oversight, and logging that contracts cannot transfer away, so selection should record which obligations each party holds and how evidence flows between them. Vendors able to produce the technical documentation and change records the Act expects are materially easier to govern. A payor that discovers after deployment that a vendor cannot support those obligations has inherited a compliance gap it must fill itself.